Subject: A survey to assess the usage pattern of aripiprazole in the management of schizophrenia in India
Schizophrenia is a complex, chronic mental health disorder characterized by an array of symptoms, including delusions, hallucinations, disorganized speech or behaviour, and impaired cognitive ability. The prevalence of schizophrenia is between 0.6% and 1.9% in the U.S. population. The prevalence of the disorder seems to be equal in males and females, although the onset of symptoms occurs at an earlier age in males than in females. In India, the prevalence of schizophrenia is about 3/1000 individuals. It is more common in men, and in terms of age of onset, men tend to be younger by an average of about five years than women when they develop schizophrenia"
Schizophrenia is characterized by positive and negative symptoms that can influence a patient's thoughts, perceptions, speech, affect, and behaviours. Positive symptoms include hallucinations, voices that converse with or about the patient, and delusions that are often paranoid. Negative symptoms include flattened affect, loss of a sense of pleasure, loss of will or drive, and social withdrawal."
Antipsychotic medications are the cornerstone of treatment for schizophrenia alongside psychosocial interventions. The selection of medication should be based on a person's past response to medication, the side effects that might be particularly harmful in individual circumstances, and routes of administration. Long term treatment with appropriate doses of antipsychotic medications is associated with a substantial increase in the life expectancy of patients with schizophrenia, compared to those who do not receive antipsychotic medication."
Aripiprazole is a quinolinone derivative with a high affinity for dopamine D2 and D3 receptors, and serotonin 5-HT1A, 5-HT2A and 5-HT2B receptors. Evidence suggests that its efficacy in the treatment of the positive and negative symptoms of schizophrenia and its lower propensity for extrapyramidal symptoms (EPS) may be attributable to aripiprazole's partial agonist activity at dopamine D2 receptors.
This survey has been undertaken to assess the usage pattern of Aripiprazole in the management of schizophrenia in India.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})